EXG102-031

N/A

Report date: 2026/03/10 20:00:16

Base Information

Drug NameEXG102-031
Drug Alias NameEXG102-031EXG102-031 (rAAV-based gene therapy)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV8 vector
Mechanisms of ActionAnti-Vascular endothelial growth factorAnti-Angiopoietin-2
TargetsVascular endothelial growth factorAngiopoietin-2
Therapy Area/IndicationsWet age-related macular degenerationMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesExegenesis Bio Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesExegenesis Bio IncExegenesis Bio Co
Inactive CompaniesN/A
Active IndicationsWet age-related macular degenerationMacular Degeneration
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A